Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 714.47 -0.66 (-0.09%) Market Cap: 78.51 Bil Enterprise Value: 71.42 Bil PE Ratio: 17.68 PB Ratio: 2.68 GF Score: 88/100

Regeneron Pharmaceuticals Inc at Guggenheim Healthcare Talks Idea Forum and Neuro/Immunology Day Transcript

Nov 18, 2019 / 04:15PM GMT
Release Date Price: $340.19 (-1.36%)
Yatin Suneja
Guggenheim Securities, LLC, Research Division - MD & Senior Biotechnology Analyst

Good morning, everyone. Welcome to Guggenheim Healthcare Talks, Idea Forum, Neuro/Immunology. It is my pleasure to introduce the next presenting company for us, this is Regeneron Pharmaceuticals. And from the company, we have the Scientific Founder, President and Chief Scientific Officer, Dr. George Yancopoulos. George, thank you so much for being here.

Before we actually go into some of the products, I mean I would acknowledge that Regeneron has been considered as one of the most scientifically-driven story under your leadership. And I'm sure investors would like to hear from you what are your current priorities in terms of drug discovery? Has it changed over the last several years that you've been with the company?

Questions & Answers

George D. Yancopoulos
Regeneron Pharmaceuticals, Inc. - Founding Scientist, President, Chief Scientific Officer & Director

Well, it's a great question. I could spend the whole time just trying to answer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot